A genetic disruption strategy developed by CU Boulder researchers effectively stymies the evolution of antibiotic-resistant bacteria such as E. coli, giving scientists a crucial leg up in the ongoing battle against deadly superbugs.
These multidrug-resistant pathogens—which adapt to current antibiotics faster than new ones can be created—infect nearly 2 million people and cause at least 23,000 deaths annually in the U.S., according to data from the Centers for Disease Control.
In an effort to develop a sustainable long-term solution, CU Boulder researchers created the Controlled Hindrance of Adaptation of OrganismS (CHAOS) approach, which uses CRISPR DNA editing techniques to modify multiple gene expressions within the bacteria cells, stunting the pathogen’s central processes and thwarting its ability to evolve defenses.
The findings are outlined today in the journal Communications Biology and could open new research avenues on how to best restrict a pathogen’s antibiotic resistance.
“We now have a way to cut off the evolutionary pathways of some of the nastiest bugs and potentially prevent future bugs from emerging at all,” said Peter Otoupal, lead author of the study and a doctoral researcher in CU Boulder’s Department of Chemical and Biological Engineering (CHBE).
The CHAOS research is the culmination of work that began in 2013, when Otoupal and his colleagues began searching for genes that could act as a cellular kill switch for E. coli. When the scientists tweaked one gene at a time, the bacteria could adapt and survive. But when they altered two or more genes at once, the cell got weaker.
“We saw that when we tweaked multiple gene expressions at the same time—even genes that would seemingly help the bacteria survive—the bacteria’s fitness dropped dramatically,” Otoupal said.
The CHAOS method takes advantage of this effect, pulling multiple genetic levers in order to build up stress on the bacterial cell and eventually trigger a cascading failure, leaving the bug more vulnerable to current treatments. The technique does not alter the bug’s DNA itself, only the expression of individual genes, similar to the way a coded message is rendered useless without the proper decryption.
“You can think of it in terms of a series of escalating annoyances to the cell that eventually cause it to weaken,” said Anushree Chatterjee, senior author of the study and an assistant professor in CHBE. “This method offers tremendous potential to create more effective combinatorial approaches.”
Although E. coli has nearly 4,000 individual genes, the exact gene modification sequence appears to matter less than the sheer number of genes that are disrupted, Otoupal said. Still, the researchers plan to continue optimizing the CHAOS method to seek out the most efficient disruptions.“Diseases are very dynamic, so we need to design smarter therapies that can gain control over their rapid adaptation rates,” Chatterjee said. “The emphasis in our lab is demonstrating the efficacy of these methods and then finding ways to translate the technology to modern clinical settings.”
“In the past, nobody really considered that it might be possible to slow down evolution,” Otoupal said. “But like anything else, evolution has rules and we’re starting to learn how to use them to our advantage.”
Learn more: How to stop an antibiotic-resistant superbug
The Latest on: Genetic disruption
[google_news title=”” keyword=”genetic disruption” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Genetic disruption
- Understanding Parkinson's Disease: Study Highlights Role Of Genetic Variants And Pesticide Exposureon April 27, 2024 at 6:31 pm
These genetic variants were found to be deleterious to protein function, suggesting a potential mechanism linking pesticide exposure, lysosomal dysfunction, and Parkinson's disease. Disruption of ...
- U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia Bon April 26, 2024 at 7:45 am
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the ...
- US approves gene therapy treatment for hemophiliaon April 26, 2024 at 7:04 am
Pharmaceutical giant Pfizer has received US approval for a gene therapy against a form of hemophilia, a rare and inherited blood clotting disorder, the company said Friday.Pfizer's genetic therapy ...
- FDA approves Pfizer's first gene therapy for rare inherited bleeding disorderon April 26, 2024 at 6:34 am
The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S.
- The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Expertson April 26, 2024 at 5:12 am
Blueprint Medicines (NASDAQ:BPMC) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the ...
- Breaking the spell: Learn the trick of decoding scientific plant nameson April 26, 2024 at 2:29 am
Ancient Greek and Roman scholars sought to bring some order to understanding of the plant kingdom by recording plant names.
- Genetic Variants May Amplify Parkinson’s Risks — But How?on April 25, 2024 at 10:22 pm
Lysosomal Genes Contribute to Parkinson’s Disease near Agriculture with High-Intensity Pesticide Use - (https://www.nature.com/articles/s41531-024-00703-4) ...
- Genetic variants linked to Parkinson's risk from pesticide exposureon April 25, 2024 at 9:20 pm
A new UCLA Health study found certain genetic variants could help explain how long-term pesticide exposure could increase the risk of Parkinson's disease.
- RNA Modification Behind Disruption of Mitochondrial Protein Synthesis in Alzheimer’son April 25, 2024 at 5:00 pm
In body cells, mRNA carries the genetic information and – together with tRNA – is responsible for its translation into proteins. Methylation of mRNA leads to a change to its chemical structure so that ...
via Bing News